Eddie Hickman
Stock Analyst at Guggenheim
(4.59)
# 947
Out of 5,081 analysts
47
Total ratings
65.2%
Success rate
30.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Reiterated: Buy | $69 → $100 | $8.06 | +1,140.69% | 8 | Aug 14, 2026 | |
| GHRS GH Research | Reiterated: Buy | $34 → $40 | $19.18 | +108.55% | 5 | Aug 6, 2026 | |
| ZVRA Zevra Therapeutics | Reiterated: Buy | $24 → $23 | $9.53 | +141.34% | 9 | Aug 6, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $90 → $89 | $70.03 | +27.09% | 16 | Jul 21, 2026 | |
| OTLK Outlook Therapeutics | Downgraded: Hold | n/a | $0.5133 | n/a | 7 | Aug 28, 2025 | |
| IMVT Immunovant | Reiterated: Buy | $44 | $28.17 | n/a | 2 | Aug 11, 2025 |
ProMIS Neurosciences
Aug 14, 2026
Reiterated: Buy
Price Target: $69 → $100
Current: $8.06
Upside: +1,140.69%
GH Research
Aug 6, 2026
Reiterated: Buy
Price Target: $34 → $40
Current: $19.18
Upside: +108.55%
Zevra Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $24 → $23
Current: $9.53
Upside: +141.34%
Tarsus Pharmaceuticals
Jul 21, 2026
Reiterated: Buy
Price Target: $90 → $89
Current: $70.03
Upside: +27.09%
Outlook Therapeutics
Aug 28, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.5133
Upside: n/a
Immunovant
Aug 11, 2025
Reiterated: Buy
Price Target: $44
Current: $28.17
Upside: n/a